Meridian Bioscience, Inc. (NASDAQ: VIVO) and Exalenz Bioscience Ltd. (TASE: EXEN) announced today that the two companies have entered into a definitive agreement for Meridian to acquire Exalenz for ₪6.10 per share in cash with an implied transaction value of approximately $49 million. The agreement has been approved unanimously by the boards of directors of both companies. With this acquisition, Meridian will be adding Exalenz’s flagship BreathID® Breath Test Systems, a urea breath test platform for the detection of Helicobacter pylori, often associated with peptic ulcers and gastric cancer.
Read the full article: Meridian Bioscience Signs Definitive Agreement to Acquire Exalenz Bioscience //
Source: https://www.globenewswire.com/news-release/2020/02/19/1987079/0/en/Meridian-Bioscience-Signs-Definitive-Agreement-to-Acquire-Exalenz-Bioscience-Adds-State-Of-The-Art-Urea-Breath-Test-Diagnostics-Platform.html